AQP5 and chronic myelogenous leukemia, BCR-ABL1 positive: On the other hand, AQP5 expression level was relatively higher among CML patients who gained imatinib mesylate resistance at chronic phase than those who gained resistance at accelerated, or blast crisis, phase.